13 August 2026
August BNF + BNFC Knowledge Updates
British National Formulary
This update contains 17 significant changes, 1 dose change, 3 classification changes, 3 new monographs, 3 new preparations and 4 deleted preparations.
Significant changes
Chronic obstructive pulmonary disease: updated guidance on the use of dupilumab.
Conjugated oestrogens: contra-indications, cautions, and hepatic impairment information reviewed.
Diphtheria with tetanus, pertussis, hepatitis B, poliomyelitis and haemophilus influenzae type b vaccine: name change to diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and haemophilus influenzae type b vaccine.
Estradiol (Estring®): indication changed from postmenopausal urogenital conditions (not suitable for vasomotor symptoms or osteoporosis prophylaxis) to genitourinary symptoms of menopause in perimenopausal, menopausal, and postmenopausal females.
Estradiol: indication changed from vaginal atrophy in postmenopausal women to genitourinary symptoms of menopause in perimenopausal, menopausal, and postmenopausal females; contra-indications, cautions, and hepatic impairment information reviewed.
Estriol: indication changed from vaginal atrophy in postmenopausal women to genitourinary symptoms of menopause in perimenopausal, menopausal, and postmenopausal females; contra-indications, cautions, and hepatic impairment information reviewed.
European viper snake venom antiserum: name change to european viper snake venom antisera.
Herpes-zoster vaccine (recombinant, adjuvanted): name change to herpes-zoster vaccine.
Menopause: new guidance on the management of menopause.
Mepolizumab: new indication and dose for uncontrolled chronic obstructive pulmonary disease, severe chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
Ospemifene: indication changed from moderate to severe symptomatic vulvar and vaginal atrophy [in post-menopausal women who are not candidates for local vaginal oestrogen therapy] to genitourinary symptoms of menopause in perimenopausal, menopausal, and postmenopausal females.
Prasterone: indication changed from vulvar and vaginal atrophy [in postmenopausal women with moderate to severe symptoms] to genitourinary symptoms of menopause in perimenopausal, menopausal, and postmenopausal females; contra-indications and cautions reviewed.
Sex hormones: this treatment summary has been replaced by the new Menopause treatment summary.
Tranexamic acid: new important safety information on serious adverse effects due to administration errors.
Urinary incontinence and pelvic organ prolapse in females: updated guidance on use of vaginal oestrogens.
Vaginal and vulval conditions: updated guidance on use of vaginal oestrogens.
Varicella-zoster vaccine: name change to varicella vaccine.
Dose changes
Vitamins A, C and D [update to age range].
Classification changes
Benralizumab [primary classification changed to Interleukin inhibitors].
Mepolizumab [primary classification changed to Interleukin inhibitors].
Reslizumab [primary classification changed to Interleukin inhibitors].
New Monographs
Exdensur® [depemokimab].
Leqselvi® [deuruxolitinib].
Ziihera® [zanidatamab].
New Preparations
Jakavi® oral solution [ruxolitinib]
Opzelura® cream [ruxolitinib]
Wegovy® 7.2 mg solution for injection in pre-filled pen [semaglutide].
Deleted Preparations
Bedol® [estradiol]
Elleste Solo® MX [estradiol]
Ovestin® [estriol]
Premarin® [conjugated oestrogens].
BNF for Children
This update contains 5 significant changes, 1 dose change, 1 classification change, 2 new monographs and 2 new preparations.
Significant changes
Diphtheria with tetanus, pertussis, hepatitis B, poliomyelitis and haemophilus influenzae type b vaccine: name change to diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and haemophilus influenzae type b vaccine.
European viper snake venom antiserum: name change to European viper snake venom antisera.
Mepolizumab: new indication and dose for eosinophilic granulomatosis with polyangiitis.
Tranexamic acid: new important safety information on serious adverse effects due to administration errors.
Varicella-zoster vaccine: name change to varicella vaccine.
Dose changes
Vitamins A, C and D [update to age range]
Classification changes
Mepolizumab [primary classification changed to Interleukin inhibitors].
New Monographs
Enflonsia® [clesrovimab].
Exdensur® [depemokimab].
New Preparations
Jakavi® oral solution [ruxolitinib]
Opzelura® cream [ruxolitinib]
